Begonya Comin-Anduix

Author

University of California, Los Angeles ORCID

Also Known As

Begonya -. Comin-Anduix, Begonya Comin-Anduix, Begonya Comin-Anduix (192236)

121

Publications

6.3K

Citations

H-Index

Concepts

All Affiliations

University of California, Los Angeles UCLA Jonsson Comprehensive Cancer Center California Institute of Technology Institute for Molecular Medicine UCLA Medical Center

About

Begonya Comin-Anduix is an author at University of California, Los Angeles specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	1.7K
2	Natural Sciences	1	1	23
3	Allergy	1	1	91
4	Biochemistry	1	1	23
5	Biomedical Engineering	1	1	92

Begonya Comin-Anduix

Publications

Citations

H-Index

Page 1

	Year	Citations
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression Ángel García-Díaz, Daniel Sanghoon Shin, Blanca Homet Moreno, Cell Reports	2017	1.8K
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction Daniel K. Wells, Marit M. van Buuren, Kristen K. Dang, Cell Tumor ImmunologyCancer ImmunosurveillanceMedicineImmunologyTumor Immunity	2020	507
A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells Chao Ma, Rong Fan, Habib Ahmad, Nature Medicine Autoimmune DiseaseMedicineT-regulatory CellImmunologyAutoimmunity	2011	439
HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression James F. Curtin, Naiyou Liu, Marianela Candolfi, PLoS Medicine	2009	366
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma Mohammad Atefi, Earl Avramis, Amanda Lassen, Clinical Cancer Research	2014	325
Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance Yapeng Su, Wei Wei, Lídia Robert, Proceedings of the National Academy of Sciences	2017	244
BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy Richard C. Koya, Stephen Mok, Nicholas Otte, Cancer Research Adoptive Cell ImmunotherapyTumor ImmunologyAntitumor ActivityTransferred CellsCancer Immunosurveillance	2012	232
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway Mohammad Atefi, Erika von Euw, Narsis Attar, PLoS ONE	2011	222
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma Erika von Euw, Thinle Chodon, Narsis Attar, Journal of Translational Medicine	2009	188
Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy Chao Ma, Ann Cheung, Thinle Chodon, Cancer Discovery	2013	146

Page 1